All lobbying filings

WILLIAMS AND JENSEN, PLLC

WILLIAMS AND JENSEN, PLLC filed a Q3 report for SANOFI, U.S. on October 20, 2025, reporting $50,000 in lobbying income.

Lobbying for SANOFI, U.S. · Global life sciences company

All filings by WILLIAMS AND JENSEN, PLLC · Everything SANOFI, U.S. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 20, 2025

Income

$50,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 3

CHRISTOPHER E. WILCOX

Previously held: LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings
JEANNE HAGGERTY

Previously held: Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member
KURT SCHRADER Former member of Congress

Previously held: Former Member of Congress

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 5

Health Issues

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. 340B, Vaccine issues.

Medicare/Medicaid

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.

Medical/Disease Research/Clinical Labs

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs.

Taxation/Internal Revenue Code

Monitor general tax issues related to international tax, vaccine excise taxes and orphan drug tax issues. H.R. 1, One Big Beautiful Bill Act.

Budget/Appropriations

Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements.

Bills named in this filing 1

H.R. 1
One Big Beautiful Bill Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.